{"name":"Evergreen Therapeutics, Inc.","slug":"evergreen-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"EG-301","genericName":"EG-301","slug":"eg-301","indication":"Other","status":"phase_2"},{"name":"EG-501","genericName":"EG-501","slug":"eg-501","indication":"Other","status":"phase_2"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"EG-007","genericName":"EG-007","slug":"eg-007","indication":"Symptomatic heart failure","status":"phase_3"}]}],"pipeline":[{"name":"EG-301","genericName":"EG-301","slug":"eg-301","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"EG-007","genericName":"EG-007","slug":"eg-007","phase":"phase_3","mechanism":"EG-007 is a selective inhibitor of the sodium- potassium pump.","indications":["Symptomatic heart failure","Reducing the risk of cardiovascular death and hospitalization in heart failure"],"catalyst":""},{"name":"EG-501","genericName":"EG-501","slug":"eg-501","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNc0tHbjVTYVgtNEt1MF9VLTNoOEtxSDM0Z0FCd1dZaTlaZHVwakl1aV9sRnB6cXV4bVBLU3hieHAxTW9EeEYtTV9fTXlESDlCVkU5c3g4Y21nR1oxVTNwSTJMeDQ4UUN1bTgybEQwR0lCaGZEcHZ3WnpTNzZJQTlBbmwxTVhvdTlHWkZpQjRZNFJzcnRydlB4WTNzS1JERjhRU1JRSmNidmxnYVVQSDdDTko1R18tdnpQQ1NtVElOQTNsVG0xV0h0RkZ1MllOT0dzZEc3WU1rZGVfQTVoZ2hyQ3UzTFl0ek5MZDBVa2VDdDVkWkkxMDBrU0ZXaTBSRFdXcEo4b00xeHVQWHFncXliNkgtSzg4eEFmUzFIUWhzOF9KdTMtRl95Uw?oc=5","date":"2026-04-02","type":"pipeline","source":"globenewswire.com","summary":"Radioligand Therapy Market Expected to Surge to $10.72 - globenewswire.com","headline":"Radioligand Therapy Market Expected to Surge to $10.72","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPd2tkNVh0Vzd0akVwRW9CX3JzSGhkM2M1UFFPX3JVR0pCRGVMcWtVVFBpQzZXUG15czI3WEhkYVE1NWRCSEt5LV9mUDZrQzhaN1VSRlpEdzZRMXNvektoc1lQZW9OODBPX2plTUM0d1hyWTVHWGdSV0x6bEtXbjRPcm92TEM5YjMzUGhiYTUxZUJ0NWc1ZUVWSUdTczhNQlgwdFYyc0p2OHBxZkVnU1dlLS1n?oc=5","date":"2026-03-24","type":"pipeline","source":"Stock Titan","summary":"NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate - Stock Titan","headline":"NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPbGQ2ZjVkM3RPV0RkbTdVbnhHMnlVMlpoaDk2dVlBZVJ6ZFhCWWFURWJvbHVfV1A4cjRkR3UwNXV4SGZ5Yl9nRV9XZ0hYVW1sM3dqZHlVNGV3S1hHRXZlZTV3UVZlTnlHbEZ3RjItdnYyRWZLNkVkM0RzTURyRktoemJnbUxyNW1zamtySmFhZXVlTER4UDRoRjI0Yno?oc=5","date":"2026-03-18","type":"trial","source":"openPR.com","summary":"Endometrial Cancer Clinical Trial Pipeline Accelerates as 50+ - openPR.com","headline":"Endometrial Cancer Clinical Trial Pipeline Accelerates as 50+","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNYXB3MDBaNkM3bmNFLWJ3Z2tBUTJpOGtLUnI3aGZnRWJQUzl5UjRfNVlSM1B3VGo1RW1XNTBTRENfdlhTaFFNaEdpVWV3U0x4eTdGZklQbUlNQ2NwTWFaZzEzd20zWnlBSUR3Q2d5bGdlMzJsTllWanZ1RWQzYVotSGhMUkMyc09jVEtzNlBDOTctZ0UtMVE?oc=5","date":"2025-12-01","type":"pipeline","source":"finance.yahoo.com","summary":"Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | DelveInsight - finance.yahoo.com","headline":"Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Comple","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQdjA4NjRPMVVoaVhDdmI1M2tpb0pyWlNpd3hTLVRNT01zNXVJc3NPQUpnUUEyV1pqZWNUN2lXdFdDX3dkcUNuTklNWU9NMzNQWGFXcGtRNF94QW5BTkhnYTBqN25OTmpBUVB4YXZTalg5UnN3TkNKZTdqa0ZyM2Njc21EX1MtQ0F6Y19pVHlNeXM0R21OV3dKaU01aHNOSzRBcV9CWWlmNFlHS25hQ3R5S1VKRjQyRmZWOWE2UHNRclJEakY4X1ZLekEtNmViMkFpclRzaldDT1RVaHBoanhNbUJBVG41NUxtTE1XUGxfa3JaZXQwUW54enQ1cFN3NmtwUTJHUlR0c0tHWHRLTDFKSlNuSnlEaUNRa2JqYXk5aGZKQTdOaTk0YTVyUnpKaHRiNDQwNmJkUFFJS2dhckhpN3BxNVkzRjg?oc=5","date":"2025-11-17","type":"pipeline","source":"globenewswire.com","summary":"Dry Age-related Macular Degeneration Market Poised for - globenewswire.com","headline":"Dry Age-related Macular Degeneration Market Poised for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogJBVV95cUxNRjQ3VUh4R0ZtbmdYQmJiNDFOSm03MXFtYXl3dG9OWV9sdlNvRlEyWXBhUmxzN3VGWktRWktnQ05tUm1RSDNBSk1mZGgzTlJSMk1kMWxYelNXUE1VdDg2WGlieE8zYzE5Sl9KWHJXYlo5N2dtTUJaWDlrMkdOeFB3ckEzeEN5V2hZNlFvTktxMDNBamFjRFdKZWtramdlR0t0T2FCQmc2OGJiSGJhZGpDdlBkNUVFcWJ2eDV4WksyOGEtQVVSbm1HWEt5WXZ1V29YTDlQTjB4d3JaUnZMOEV3ajg0U1FKTGNHdVc2aFNHWldFYXF0NTlQeWlsajJqWHJPX3NOQU8zVUdEazRUaDFBdlRGLVdYclpZSGdldWY4aWR6dw?oc=5","date":"2025-11-06","type":"trial","source":"PR Newswire","summary":"Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immunotherapies | DelveInsight - PR Newswire","headline":"Endometrial Cancer Market Poised for Expansion Throughout Forecast Period (2025-2034) Amid Increasing Adoption of Immuno","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxOQnVMZjBIMnRadVZZWkJTZGdNU3E0YkV6blU4ZTZwbEVuV09udVJvZDEzTFRmcjhjb1NhRDctNktxUHA1SmViU0xNYVNZejhOUS1XeFJVR3A2VzQ2MjAweE9EdHJJVzhMV0cxYUM0eF9CV0drVXhwbmQ2bHF2YzE5U2M5V0I5cUhtMXdFM1NjckE1dGhXR21uMzBfeWtaWEtkMkdkZnFZd1NDc3NldFFmVndCUEF3elRtNUJGMUpkLWF0UV9ITHpTOURBVS1KY3ZTN24tMWMzMlEyaGdVUXlLZ2JFRE5wWHhUODVFRGxfQlJTSXVkeTMtclBIbXVSQjJEdGxOSHFYdmxvRmtYUDN5RDdIY1NaRmZhQlpORm1oeXo1alRXbzh6SVUzT25SUlhWN3RXMkJJX1dFS2MyTF8wVjZzVGRqNkU?oc=5","date":"2025-10-23","type":"pipeline","source":"PR Newswire","summary":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight - PR Newswire","headline":"Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Dia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxOaW4zU0poVnpIb2JTODhiOEZ0a1IxRGtKYlhnMDhQelF3eU92RVRDdGdockRkYXQ5MDJLeHAzZzdEVEdhajB5dlg3UWxBanlxTkUyU2JLUWZ2TnBrNkkyMENsOWJKeE1MeHd0YVhfM2lqTTM2dERYV01SdHp0aWZWUlV5MFdlOEpDOVE3aUVTcTdNQQ?oc=5","date":"2025-07-15","type":"trial","source":"finance.yahoo.com","summary":"Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight - finance.yahoo.com","headline":"Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxNbWVCa1hVMWluMTNNd0lYX2ZMc1ZmUUFCVjNFeUJicUxOY0V3cmRWZzZEeDRpT01MWjlnVURDUjZtVm9hQXkxY0sxenc4SEdnclA5SzdVa24xMDVZUWZNWTQzR3YwMzNUYXV3M2VuOC14OFNvYWJfeVJ3RW9ZVU9sQTdmbDMzZ3FMRnMzTDBteUI4b3F1dDhkYTlqMXNsVk9JT1l3a25QT1ZJdnhiMFkzYVFpeFUzOFBoelYtcjYwb2IzMU5hMHlHTXVnbmM?oc=5","date":"2025-05-07","type":"pipeline","source":"Business Wire","summary":"Vivo Capital Closes Its Public Fund with Commitments of Over $740 Million - Business Wire","headline":"Vivo Capital Closes Its Public Fund with Commitments of Over $740 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPWHBPalFoWC1XT2JNb3VQREZhSkhmemM0Tkc1WXItWm43dlUzZWxmUUYySXlYT2lmZVUwRzg1d3l5THlYbUJwZXZaVTk0amMxWUo4bnZpTHN0V3ZNcEJ6c0RGQ19PamNLQk14emJOaFZuZ1dPWm1PZmhXbWYtQVBNRkM5aVM1Z2hPaF9Rc0RQQ2h5TkZfbV9iVEhsOEFRSDRteWU5dlZXdEpadw?oc=5","date":"2025-01-29","type":"deal","source":"Pharmaceutical Technology","summary":"Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology","headline":"Lantheus acquires radiopharma CDMO Evergreen for up to $1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQVkNPQ0lZLW1NbDVlcXlVNlNTSkpGbmFNRHZtRkNLbHdoSjFBcWVoSTctblBFR1NudUR2X04zbkxpY01VUkM5dXdLSEczWHJIOVZWSW1UODRLYmpWN2xuaEMzTGxnY1VuRXJqdVo1ZXEtY0wwdl9HRFA4QVdlVWYycEYxS0dSN25VUXh4b01VeDdSQkdKaHJRcFpEZ0dXTUU?oc=5","date":"2025-01-28","type":"deal","source":"Contract Pharma","summary":"Lantheus Holdings to Acquire Evergreen Theragnostics - Contract Pharma","headline":"Lantheus Holdings to Acquire Evergreen Theragnostics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPNjRuaV9LN0p4R09EYmN1MjZFVzFCNlZPUkFZVWt3Ykx5aUEyZjk1Ri02ZDExRVRoOTVOT3lYTkpYVlpzUWdIcFJLX0NEYVZsU1g5OGtJd0g3dl90aXhES1NlVUJzU3hFeDJJcHdUYjVsRHRUM2JLandKSEY3WTRWT2JlVlRLMTBqNkRtLUFCbmgtcGhnOFhaazZ3?oc=5","date":"2022-10-06","type":"pipeline","source":"VUMC News","summary":"VUMC to test whether Alzheimer’s drug can ease lupus symptoms - VUMC News","headline":"VUMC to test whether Alzheimer’s drug can ease lupus symptoms","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}